News

The Wellcome Trust is supporting the international research consortium FUTURE-D with nearly six million euros. Coordinated by University Hospital Frankfurt, the project is developing new data-driven approaches to detect severe and chronic forms of depression earlier and to tailor treatments more individually, thereby sparing patients from having to undergo various therapies for years before finding one that works. To achieve this, the international consortium – comprising partners from six countries – combines state-of-the-art data analysis with clinical expertise and large-scale long-term cohorts. The project launches in autumn 2026 and builds on research findings from LOEWE-DYNAMIC.

The project leadership emphasizes the innovative and holistic nature of the initiative: FUTURE-D aims to enable the detection of depressive disorders at an early stage based on reliable warning signs, rather than addressing them only when they have reached a severe stage. "With FUTURE-D, we aim to identify depression earlier and treat it in a more individualized manner in the future. This funding allows us to combine state-of-the-art data science with clinical expertise and international collaboration," explains Prof. Dr. Jonathan Repple, Professor of Predictive Psychiatry and Managing Senior Physician at the Department of Psychiatry, Psychosomatics, and Psychotherapy at University Hospital Frankfurt. Department Director Prof. Dr. Andreas Reif also views the consortium as a significant step toward more personalized care: FUTURE-D represents a paradigm shift that systematically accounts for the biological, psychological, and social complexities of depressive disorders, ultimately aiming to facilitate more precise treatment decisions. FUTURE-D brings together two of the world’s most extensive long-term cohorts for depression research: the MACS and NESDA studies. Researchers are combining methods from network science, dynamic systems modeling, and control theory to gain a better understanding of how depressive disorders originate, progress, and become destabilized. Biological and clinical factors alone are insufficient; psychosocial factors and the perspectives of those affected are also incorporated into the models. The goal is to generate insights that are not only scientifically robust but also directly applicable to patient care. Through FUTURE-D, University Hospital Frankfurt is further strengthening its international standing in translational psychiatry and personalized medicine, with the aim of predicting depressive disorders more accurately and tailoring treatments more effectively to the individual.

For further information, please contact: Prof. Dr. Jonathan Repple, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Phone: +49 69 63 01 – 67 64, E-mail:jonathan.repple@unimedizin-ffm.de  internet: www.unimedizin-ffm.de